(Q37857328)

24 August 2017

1 reference

title

Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives (English)

1 reference

24 August 2017

Newman Yeilding

1

1 reference

24 August 2017

Philippe Szapary

2

1 reference

24 August 2017

Carrie Brodmerkel

3

1 reference

24 August 2017

Jacqueline Benson

4

1 reference

24 August 2017

Michael Plotnick

5

1 reference

24 August 2017

Honghui Zhou

6

1 reference

24 August 2017

Kavitha Goyal

7

1 reference

24 August 2017

Brad Schenkel

8

1 reference

24 August 2017

Jill Giles-Komar

9

1 reference

24 August 2017

Mary Ann Mascelli

10

1 reference

24 August 2017

Cynthia Guzzo

11

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Annals of the New York Academy of Sciences

24 August 2017

published in

1 reference

24 August 2017

volume

1222

1 reference

24 August 2017

page(s)

30-39

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

24 August 2017

1 reference

Psoriasis--epidemiology and clinical spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Pathogenesis and clinical features of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Psoriasis has a major secondary impact on the lives of family members and partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

The family impact of skin diseases: the Greater Patient concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Prevalence and correlates of suicidal ideation among patients with skin disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Development, cytokine profile and function of human interleukin 17-producing helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Interleukin-12, interleukin-23, and psoriasis: current prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

The role of IL-12, IL-23 and IFN-gamma in immunity to viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

IL-23 drives pathogenic IL-17-producing CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2011.05963.X

10.1111/J.1749-6632.2011.05963.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference